2022 Cholesterol Summit

Join this free one-day virtual summit to learn strategies to close the gap in optimal cholesterol management by enhancing and empowering healthcare professionals, like you!  Tune in to hear from thought leaders across the country as they share strategies to understand and apply evidence-based National Guidelines for the management of dyslipidemia and the primary and secondary prevention of ASCVD.

This is a non-CE educational event.  While there are no continuing education credits associated with it, it is high-quality content from content experts and nationally recognized thought leaders.

Agenda

Join the webinar with the following links.

9:00 AM CT	Welcome
9:15 AM CT	Lipoprotein(a) and ASCVD Risk Marlys Koschinsky PhD, FAHA, FNLA, FCAHS, FACC, OOnt
10:00 AM CT	Homozygous Familial Hypercholesterolemia (HoFH): Patient Perspectives Seth Baum, MD, FACC, FAHA, FNPLA, FASPC Allison Jameson, Patient Advocate
10:45 AM CT	Speaker Panel
11:00 AM CT	The Role of Non-Statin Therapies in Optimal Cholesterol Management Gina Lundberg, MD
11:45 AM CT	Product Theater by Esperion A Next Step in LDL-C–Lowering Therapy: Oral Nonstatin Therapies Payal Kohli, MD
12:30 PM CT	Break
12:45 PM CT	Lunch & Learn: Overcoming Provider and Patient Inertia Lisa Maher, DNP, ARNP, FNP-BC, FPCNA Marla Cohen, Patient Advocate
1:30 PM CT	Improving Adherence to Cholesterol Lowering Therapies Lynne Braun, PhD, CNP, FPCNA, FAHA, FAANP, FNLA, FAAN
2:15 PM CT	Speaker Panel
2:30 PM CT	Transitioning from Acute to Chronic Lipid Management Joe Saseen, PharmD, FNLA, CLS
3:15 PM CT	Wrap-up

Learning Objectives

Lipoprotein(a) and ASCVD Risk

1. Describe Lipoprotein(a) and measurement practices
2.  Explore the link between Lipoprotein(a), ASCVD risk, and family history
3. Discuss current and future treatments for Lipoprotein(a)
4. Review a case study on the explanation of elevated Lipoprotein(a) risk and initial diagnosis

Homozygous Familial Hypercholesterolemia (HoFH): Patient Perspectives

1. Describe HoFH including etiology, prevalence, signs, and symptoms
2. Hear from patients and families as they discuss the effects of HoFH
3. Explore shared decision making in the testing and treatment of HoFH

The Role of Non-Statin Therapies in Optimal Cholesterol Management

1. Explore residual ASCVD risks and solutions for closing the treatment gap
2. Explain statin side effects and intolerance
3. Explore the undertreatment risk in Familial Hyperlipidemia
4. Identify strategies to increase compliance to medication regimens

Transitioning from Acute to Chronic Lipid Management

1. Discuss patient and family education techniques taking into consideration the social detriments of health present and the patient perspective
2. Discuss the medications and health conditions that can increase cholesterol
3. Review discharge planning considerations to overcome barriers to treatment adherence

Overcoming Provider and Patient Inertia

1. Discuss patient-centric guideline translation
2. Explain the benefits of a team-based approach to patient care
3. Explore enhancing care by using the electronic health record and decision support

Improving Adherence to Cholesterol-Lowering Therapies

1.  Explore patient-centered care and joint decision-making
2. Explore health disparities and cultural concerns present in medication adherence
3. Discuss resources to overcome barriers to adherence including the cost of medications and complex treatment regimens
   

Thank you for the independent educational grants from Amgen Inc., Esperion Therapeutics, Inc., Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals, Inc.